<DOC>
	<DOCNO>NCT00570336</DOCNO>
	<brief_summary>The purpose study determine CTS-1027 low elevate liver enzyme patient chronic HCV infection .</brief_summary>
	<brief_title>Study CTS-1027 Hepatitis C Patients</brief_title>
	<detailed_description>Randomized , placebo-controlled , double-blind , parallel group , multicenter , dose response trial utilize four dos CTS-1027 , administer orally daily , outpatient chronic hepatitis C virus ( HCV ) infection .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Male female patient minimum adult legal age ( accord local law sign informed consent document ) , able provide write informed consent , understand comply requirement trial A history chronic HCV infection Unsuccessful HCV treatment define one follow criterion : 1 . Failure achieve virologic response previous therapy , 2 . Failure tolerate therapy , 3 . Failure maintain sustain virologic response , 4 . In opinion Principal Investigator , patient suitable candidate interferon base therapy Liver impairment , define either aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) level 1.5 7 x ULN least two occasion , seven day apart , baseline period Alphafetoprotein ( AFP ) &lt; = 50 ng/mL Hemoglobin &gt; = 10 g/dL , platelet count &gt; = 75 x 109/L , white blood cell count &gt; = 1.5 x 109/L Willingness utilize adequate contraception ( female , evidence postmenopausal least 6 month use contraceptive pill ; female male , surgically sterile , use two form barrier contraception ) screen least one month completion trial . Decompensated severe liver disease define one follow criterion : 1 . Prior liver biopsy show cirrhosis 2 . Prior liver biopsy show bridge fibrosis ( Metavir &gt; 2 Ishak &gt; 3 ) 2 year ago absence new liver biopsy result 3 . Prothrombin time : 3 second &gt; control 4 . Total bilirubin &gt; = 1.5 x Upper limit normal range ( ULN ) , &gt; 3 x ULN unconjugated bilirubin 5 . Serum albumin normal limit 6 . AST ALT &gt; 7 x ULN baseline period 7 . Evidence portal hypertension include : Splenomegaly evidence portal hypertension ( i.e. , enlarge portal vein varix ) ultrasound , Varices esophagogastroduodenoscopy ( EGD ) ; Ascites Hepatocellular carcinoma ( HCC ) suspicion HCC clinically ultrasound ( image technique ) Known history presence human immunodeficiency virus ( HIV ) infection Coinfection hepatitis B virus ( HBV ) If female : pregnant , lactating , positive serum urine pregnancy test Last baseline AST ALT level prior Day 1 &lt; 1.5 x ULN Renal impairment ( creatinine &gt; 1.5 x ULN ) hepatorenal syndrome Pancreatitis Hospitalization liver disease within 60 day screen Use concomitant prior drug therapy HCV screening , include use : 1. drug presumed antiHCV activity prior three month 2. corticosteroid past 30 day 3. potentially hepatotoxic drug past 30 day ( include alpha methyldopa , sodium valproic acid , isoniazide , nitrofurantoin ) Use illicit drug abuse prior three month ( allow medically prescribe indicate ) History alcohol abuse within past year History presence clinically concern cardiac arrhythmias prolongation predose QT QTc interval &gt; 450 millisecond Other concomitant disease condition likely significantly decrease life expectancy ( e.g. , moderate severe congestive heart failure ) malignancy curatively treat skin cancer ( basal cell squamous cell carcinoma ) , unless adequately treated complete remission ten year Any patient receive investigational drug device within 30 day dose , schedule receive another investigational drug device course trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>HCV</keyword>
	<keyword>HCV treatment failure</keyword>
	<keyword>Elevated aminotransferase</keyword>
</DOC>